Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Broad Institute Targets Cellular Traffic Jam, Reverses Diseases in Mice

Broad Institute Targets Cellular Traffic Jam, Reverses Diseases in Mice

November 19, 2026 Health Desk Health

More than 50 inherited diseases share a single cellular flaw, and this week a Broad Institute team reported a therapy that fixed it in mice.

  • Broad Institute researchers identified a four-protein complex — TMED2, 7, 9 and 10 — that traps misfolded proteins and jams the cell’s quality-control machinery.
  • Disrupting the complex in mice reversed hallmarks of MUC1 kidney disease and slowed vision loss in a model of retinitis pigmentosa.
  • TMED7 emerged as the strongest single target, and drug candidates against it are now in development for liver and brain diseases as well.

The diseases in question, called proteinopathies, arise when mutated proteins fail to fold correctly, accumulate inside cells and eventually kill them. Each condition on its own is rare and attracts little investment, but the shared mechanism changes the arithmetic, the team argues in a study published in Neuron.

Anna Greka, a core institute member of the Broad and the paper’s senior author, who is also a professor at Harvard Medical School and a physician in the Department of Medicine at Mass General Brigham, put the stakes plainly.

“We’ve identified a shared mechanism behind many seemingly disparate diseases that, on their own, are each quite rare and don’t drive a lot of investment for therapeutic development,” said Anna Greka, a core institute member of the Broad and senior author of the new paper. “But put all these conditions together, and a drug treating all of them is suddenly something that could benefit millions of patients.”

Four proteins trap the cell’s cargo

The finding extends work the same lab published in 2019. Back then, the group showed that in MUC1 kidney disease, a protein called TMED9 — meant to shuttle misfolded proteins through the cell’s quality-control system — became overwhelmed, stayed latched onto the defective cargo, and jammed the entire production line. Disabling TMED9 released the misfolded protein for recycling by the cell’s lysosome, restoring normal traffic.

The initial discovery looked like a solved problem, Greka said. It was not. The TMED family comes in nine versions that can combine in many ways, so the team mapped which combinations matter. Four of them — TMED2, TMED7, TMED9 and TMED10 — assemble into a complex that traps misfolded proteins. That complex is the entrapment point the new therapy attacks.

Story on The Morning Science
Photo: themorning.science

“All those TMEDs have regular roles in quality control in healthy cells,” explained Magdalena Riedl Khursigara, who works as a postdoctoral researcher in Greka’s lab and shares first authorship of the new study with Alissa Goss, formerly an M.D.-Ph.D. student.

“Misfolding happens all the time on a low level and this complex handles it. But in these genetic disorders, there’s just a huge amount of misfolded protein burden, because it’s continuously being produced due to a genetic mutation.”

TMED7 deletion reversed disease in mice

One protein held the complex together more potently than the rest: TMED7. When the researchers deleted the gene for TMED7 in mice with MUC1 kidney disease, the hallmarks of the kidney disease reversed. In a mouse model of retinitis pigmentosa, a rare genetic eye disorder, removing TMED7 slowed vision loss.

The intervention left the healthy traffic system untouched. Removing TMED7 stopped the buildup of mutated proteins without preventing the other TMEDs from carrying out their normal quality-control duties — a specificity problem that has sunk many protein-misfolding therapies before.

“If you knock out just TMED7 in a genetic model, then the entrapment of misfolded proteins is released but the other TMEDs remain stable,” said Riedl Khursigara. “That’s why we think this is an especially good protein to target.”

The team also developed a small molecule that targets this trafficking machinery, and per the Broad Institute’s own announcement, that molecule worked in mice against both diseases. The Broad Institute, which carried the institute’s report by Corie Lok on November 19 at 16:00 UTC, said that the strategy has not yet been shown in humans — a caveat that frames every result above.

One mechanism, many organs

Greka described the pattern as “nodal biology”: distinct diseases sharing common biological nodes that a single drug can hit. Her collaborators are already testing TMED-targeting molecules in liver and brain proteinopathies, the report said.

The work runs through the Ladders to Cures Accelerator at the Broad, which Greka founded to speed development of precisely these cross-disease treatments, and the new paper, she said, is laying the foundation for those future therapeutic programs.

Mouse efficacy is where this story ends and preclinical development begins. Molecules cleared in animal models still face toxicity profiling, dosing studies and eventual human trials before any patient could see benefit — steps the sources did not yet date or detail.

Seven years from one protein to a platform

The arc is instructive for how rare-disease drug development now works. In 2019, the lab had one protein, one disease, one observation: TMED9 jams in MUC1 kidney disease. By 2026, that observation has grown into a four-protein complex, a named target in TMED7, a small molecule with efficacy in two unrelated organs in mice, and a pipeline testing liver and brain applications.

If the underlying hypothesis holds, the more than 50 proteinopathies the sources cite — kidney, eye, liver and brain disorders alike — share an addressable point of failure, and each new organ tested tests the platform rather than a new mechanism.

“This paper is laying the foundation for some of these future therapeutic programs,” Greka said; she likewise serves on the faculty of Harvard Medical School and practices medicine in the Department of Medicine at Mass General Brigham.

The Broad Institute, where the research was carried out, is a biomedical and genomic research center in Cambridge, Massachusetts, formally launched in May 2004 after philanthropists Eli and Edythe Broad made a founding gift of $100 million to unite MIT, Harvard and the Harvard-affiliated hospitals in a single collaborative organization.

It grew out of a decade of joint research, including the Whitehead Institute’s Center for Genome Research, a major center for the Human Genome Project.

Today the institute counts 24 core faculty members, including Greka, alongside 195 associate members, and its scientists pursue programs ranging from cancer and chemical biology to psychiatric research. During the COVID-19 pandemic, the Broad processed one out of every 20 COVID-19 tests in the United States as of September 2020.


Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • Australian Team Develops Nasal mRNA Alzheimer’s Therapy, Mouse Tests Show Cognitive Benefit
  • Guiding Stars: Diet Key to Skin Health, Nov 19 Report

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service